Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT: Inebilizumab in Adults With Myasthenia Gravis
NCT04524273Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2020
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of inebilizumab in myasthenia gravis (MG), sponsored by Amgen. Started Oct 2020; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04524273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524273.